Navigation Links
Rigged to explode?
Date:1/19/2012

An inherited mutation in a gene known as the guardian of the genome is likely the link between exploding chromosomes and some particularly aggressive types of cancer, scientists at the European Molecular Biology Laboratory (EMBL), the German Cancer Research Centre (DKFZ) and the University Hospital, all in Heidelberg, Germany, have discovered. Their study, published online today in Cell, also presents the first whole genome sequence of a paediatric tumour: medulloblastoma, a brain cancer which is the second most common cause of childhood mortality in developed countries, where only car accidents cause more deaths in children.

Looking at the complete genome sequence of these tumours, the scientists found one or two chromosomes in each cell had countless parts in the wrong order, were missing some genes, and had extra copies of others. Such extensive rearrangements suggested that those chromosomes had been shattered, like a bead necklace that is pulled too hard, and then wrongly reassembled. But the scientists only found these telltale signs of chromosome explosion, or chromothripsis, in samples from a specific group of patients.

"All patients who had inherited a mutation in the TP53 gene showed signs of chromothripsis in their tumour cells, but none of the patients with normal TP53 did" says Jan Korbel, who led the genomics research at EMBL, "so this mutation must be involved either in shattering chromosomes, or in preventing the cell from reacting when a chromosome shatters."

This strong link between the hereditary TP53 mutation and chromothripsis has implications for diagnosis and treatment.

"As clinicians, if we find evidence of chromothripsis in a medulloblastoma sample, we can now look for an inherited mutation in the TP53 gene" says Stefan Pfister, who led the work at the DKFZ, "and we know that any family members who also have the mutation should be screened regularly, as they'll have a very high risk of developing particular types of cancer, including brain tumours."

Cancer treatments often involve killing the tumour cells by damaging their DNA with chemo- or radiotherapy, but these treatments also affect healthy cells in the surrounding tissue. If those cells have healthy copies of p53 the protein encoded by TP53 this gene will monitor the genome, and if it finds too much damage it will instruct the cells to stop dividing, sending them into the cellular equivalent of old age (senescence) or suicide (apoptosis). But if a patient has inherited the TP53 mutation from their parents, all their cells will have faulty copies of this gene, including the cells surrounding the tumour. Thus, those healthy cells will have trouble dealing with the DNA damage caused by such treatments, and could become cancerous themselves. So the findings have immediate clinical implications in that such patients should not be given DNA-damaging chemotherapy or high-dose radiotherapy, since both would greatly increase the likelihood of secondary cancers.

The scientists believe that the TP53 mutation may also play a role in causing chromosomes to shatter in the first place, by shortening telomeres, the caps that keep chromosome ends from fraying. This could make arms from different chromosomes more likely to get stuck to each other and shatter if they're pulled in different directions. Since telomeres naturally shorten with age, this could explain why, when the German scientists expanded their study to another cancer an aggressive form of leukaemia in adults they found that patients who had both a non-inherited TP53 mutation and evidence of chromothripsis were typically of an advanced age.

"Chromothripsis is thought to cause two to three percent of all human cancers," says Korbel, "so if we can really prove how the TP53 mutation affects this process, it could have a big impact on our understanding of how healthy cells in the body turn into tumours."

The study was undertaken as part of the International Cancer Genome Consortium (ICGC), an effort to study 50 different types of cancer worldwide.

"This study shows the power of combining genome sequencing and clinical expertise," says Peter Lichter from DKFZ, and member of the ICGC scientific steering committee: "cancer genome sequencing can help to understand why patients can react so differently to cancer treatments, and may also lead to the development of new anti-cancer drugs."


'/>"/>

Contact: Sonia Furtado Neves
sonia.furtado@embl.de
European Molecular Biology Laboratory
Source:Eurekalert  

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rigged to explode?
(Date:9/21/2017)... ... September 21, 2017 , ... Preora Diagnostics Inc. ... screening tests, has received two prestigious recognitions that acknowledge the promise of its ... Preora has been named a Top 100 Finalist for the 16th annual ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand ... to detail to the athletic wear market with the launch of their FlipBelt Crops. ... have their essentials securely at their fingertips while at the gym, on the trail, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Month, Lewis and Clark College Emeritus Professor of Education Gregory A. Smith examines ... of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Coating System for clients that rely on safety and cleanliness. This unique flooring ... , Silver has been used for centuries for its antimicrobial properties. Unlike antibiotics, ...
(Date:9/20/2017)... ... ... Doctors on Liens has added the medical group Bones and Spine Surgery, ... personal injury lien basis. Founded by Dr. Wayne Cheng, MD and Dr. Gordon Yee, ... orthopedic injuries to patients in the Inland Empire. , Bones and Spines Surgery Inc ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
(Date:8/28/2017)... Holdings, Inc. (NYSE: HRC), will present at the Morgan Stanley ... New York . John Greisch , Hill-Rom,s ... 11:05 a.m. Eastern Time. The live audio ... replay will be available one hour after the conclusion of ... About Hill-Rom Holdings, Inc. Hill-Rom ...
Breaking Medicine Technology: